Cholera Vaccines Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The cholera vaccines market encompasses prophylactic vaccines designed to prevent infection caused by Vibrio cholerae, the bacterium responsible for cholera. The market is valued at approximately $103 million globally and is experiencing steady growth as public health authorities prioritize preventive immunization over reactive outbreak response. Oral cholera vaccines, administered in one or two doses, dominate the market due to their ease of delivery and established efficacy profiles.

• •WHO-prequalified oral vaccines include Dukoral, Shanchol, Euvichol-Plus, and Vaxchora
• •Vaccines are primarily deployed through mass vaccination campaigns and routine immunization in endemic areas
• •International health organizations maintain strategic stockpiles for rapid outbreak response

Recurring cholera outbreaks across sub-Saharan Africa, South Asia, and parts of the Middle East are fueling demand for preventive vaccination programs. The World Health Organization's Global Roadmap to 2030 targets a 90% reduction in cholera deaths and elimination of transmission in multiple countries, creating sustained government and NGO procurement activity. Improved vaccine affordability and the introduction of lower-cost formulations have expanded access in low-resource settings.

• •Climate change and extreme weather events increasingly disrupt water and sanitation infrastructure
• •WHO and GAVI-supported vaccination campaigns in endemic hotspots drive institutional demand
• •Favorable safety profiles and ease of oral administration support adoption in field settings

The market is segmented by vaccine type, with whole-cell inactivated oral cholera vaccines representing the dominant category. Dukoral, Shanchol, Euvichol-Plus, and Vaxchora comprise the primary products, each differing in formulation, dosing schedule, and target populations. Geographically, Asia-Pacific accounts for the largest regional share due to high endemicity in countries like India, Bangladesh, and Vietnam, while sub-Saharan Africa represents the fastest-growing region as vaccination scale-up accelerates.

• •Killed/oral inactivated vaccines hold the majority market share; live attenuated candidates are in development
• •End-user segments include government public health programs, NGOs, and institutional buyers
• •India, Bangladesh, and African nations including Ethiopia and Somalia are key demand centers

What are the recent trends and outlook?

The market is expected to maintain a 9.68% CAGR through the forecast period, supported by expanding preventive vaccination strategies and growing integration of cholera vaccines into routine immunization schedules in high-risk countries. Development of thermostable formulations and simplified single-dose regimens could further improve accessibility in remote settings. Increased emphasis on the One Health approach, addressing the human-animal-environment interface of cholera transmission, may shape future vaccine deployment and surveillance strategies.

• •Single-dose and thermostable vaccine candidates in clinical development could broaden field utility
• •Cholera vaccine integration into routine childhood immunization programs is gaining policy traction
• •Strategic stockpile expansion and regional manufacturing initiatives aim to improve supply security